This inventor holds 83 USPTO granted patents and 31 published patent applications, plus 8 CIPO patents and 10 EPO patents, primarily in Therapeutic Nucleases (CPC class C07K2319-30). Top assignees: Bristol-Myers Squibb Compnay, University of Washington, Emergent Product Development Seattle,llc. Active years: 1987-2025.
Inventors with similar research interests:
Location History:
- Shorline, WA (US) (2014)
- Seattle, WA (US) (1987 - 2022)
- Shoreline, WA (US) (2006 - 2022)
Company Filing History:
37 out of 3,735 
11 out of 2,166 
8 out of 11 
Years Active: 1987-2025
Areas of Expertise:
Title: Innovations in Therapeutics: The Patented Works of Jeffrey A. Ledbetter
Introduction
Jeffrey A. Ledbetter, a prolific inventor located in Shoreline, WA, has made significant contributions to the field of biotechnology with a remarkable portfolio of 77 patents. His innovative work primarily focuses on the development of fusion polypeptides that hold promise for therapeutic applications.
Latest Patents
Among his latest patents, Ledbetter has disclosed compositions and methods related to paraoxonase fusion polypeptides. These innovations encompass bispecific molecules that include biologically active polypeptides linked to paraoxonase, thereby showcasing a versatile approach toward therapeutic solutions. Additionally, his patent on polynucleotides encoding ApoA-1 fusion polypeptides further highlights his multifaceted approach in combining different biological activities to enhance therapeutic efficacy.
Career Highlights
Throughout his career, Ledbetter has been associated with prominent companies such as Bristol-Myers Squibb Company and Emergent Product Development Seattle, LLC. His experience in these esteemed organizations has undoubtedly provided him invaluable insights into the pharmaceutical and biotechnological landscapes, enabling him to innovate effectively.
Collaborations
Ledbetter has collaborated with notable peers in the field, including Martha Susan Hayden-Ledbetter and William Brady. These collaborations have likely fostered a dynamic exchange of ideas, further enhancing his research endeavors and patent outputs.
Conclusion
In conclusion, Jeffrey A. Ledbetter stands out as a significant figure in the realm of biotechnology innovations. His extensive patent portfolio and collaborative efforts position him as a leader in developing novel therapeutic methods that could shape future healthcare advancements.